Augmedix (AUGX)
(Delayed Data from NSDQ)
$0.78 USD
-0.02 (-3.06%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $0.78 0.00 (0.45%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AUGX 0.78 -0.02(-3.06%)
Will AUGX be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for AUGX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AUGX
Health Catalyst (HCAT) Q1 Earnings Beat Estimates
How Much Upside is Left in Augmedix, Inc. (AUGX)? Wall Street Analysts Think 36.67%
AUGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Augmedix, Inc. (AUGX) is on the Move, Here's Why the Trend Could be Sustainable
Privia Health (PRVA) Q3 Earnings Miss Estimates
Definitive Healthcare Corp. (DH) Soars 7.1%: Is Further Upside Left in the Stock?
Other News for AUGX
Augmedix Maintains Financial Outlook and Hosts Investor Chat
Analysts Conflicted on These Healthcare Names: Inotiv (NOTV), BioNTech SE (BNTX) and Augmedix (AUGX)
Augmedix Reiterates Second Quarter and Full Year 2024 Outlook
Augmedix reiterates FY24 revenue $52M-$55M, consensus $53.21M
Predictive Oncology, Augmedix, Cue Health among healthcare movers